魏则西细胞免疫治疗“临床应用”（临床研究）讨论转帖

StephenW

吕邱露薇 发表于 2016-5-11 09:45
从历史的经验看，但凡是激烈争吵的，总会有一方是老王的马甲，但这次我真的晕了，没看出来。 ...

看看镜子

MP4

http://news.xinhuanet.com/health/2017-06/20/c_1121175176.htm
任军团队在国际期刊发文阐释细胞免疫治疗新进展
  首都医科大学任军教授研究团队于2017年1月在国际期刊Clinical Cancer Research (IF=9.619)上发表论文，题目为“Dendritic cell/cytokine induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: A prospective study”。

        该项前瞻性研究比较了树突状细胞诱导的杀伤细胞免疫治疗（DC-CIK）联合口服化疗药S-1治疗晚期胰腺癌患者，与单纯S-1化疗或单纯DC-CIK免疫治疗，以及合适支持治疗，三组的研究数据显示，总生存时间分别为212天，128天及141天，细胞联合免疫治疗联合S-1化疗，未增加化疗药的毒副反应，却能有效延长患者的生存时间，肿瘤标志物CEA、CA-199也显著降低。且接受两周期以上的细胞免疫治疗相比单周期的患者，临床获益更为显著。同时，CD3+, CD3+/CD4+ 和CD8+/CD28+ T淋巴细胞比例显著上升，提示细胞免疫治疗有助于调节宿主免疫微环境。对循环游离细胞（cfDNA）检测的结果也发现，肿瘤的突变频率与细胞免疫治疗的疗效有显著相关性。

        此研究与美国杜克大学医学中心合作，立足于临床，利用双方联合共建的国内唯一的“肿瘤治疗性疫苗北京市重点实验室”平台 ，以转化研究带动临床个体化治疗，展现了肿瘤免疫治疗真实、可靠、完整临床研究结果，使我国肿瘤免疫治疗研究水平达到国际领先水平。（文/闻卓）

Dendritic cell/cytokine induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: A prospective study.
Jiang N, et al. Clin Cancer Res. 2017.
Authors
Jiang N1, Qiao G2, Wang XL3, Morse MA4, Gwin WR5, Zhou L6, Song Y2, Zhao Y2, Chen F7, Zhou XN3, Huang L1, Hobeika A8, Yi X9, Xia X10, Guan Y9, Song J11, Ren J12, Lyerly HK13.
Author information
1Department of Medical Oncology, Beijing Shijitan Hospital,Capital Medical University Cancer Center.
2Beijing Shijitan Hospital,Capital Medical University Cancer Center.
3Oncology, Beijing Key Laboratory of Cancer Therapeutic Vaccine, Beijing Shijita Hospital, Capital Medical University.
4Medicine / Medical Oncology, Duke Univ Medical Ctr.
5Department of Medicine, University of Washington.
6Tumor, Shijitan Hospital.
7Department of Hematology, Qilu Hospital of Shandong University.
8Surgery, Duke University Medical Center.
9Geneplus-Beijing, Geneplus-Beijing.
10Geneplus-Beijing Institute.
11R&D center, Geneplus-Beijing Institute.
12Department of Medical Oncology, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University [email protected].
13Dept of Pathology, Duke University Medical Center.
Citation
Clin Cancer Res. 2017 Jun 13. pii: clincanres.0492.2017. doi: 10.1158/1078-0432.CCR-17-0492. [Epub ahead of print]
Abstract
Purpose: Advanced pancreatic cancer has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine induced killer cells (DC-CIK) administered with the chemotherapy (CT) S-1 in this malignancy. <p> Experimental Design: Consecutive patients (n=47) with advanced pancreatic cancer were treated with either DC-CIK + S-1, DC-CIK alone, S-1 alone, or best supportive care.</p> <p> Results: DC-CIK plus S-1 produced significantly longer median OS and PFS (212 and 136 days) compared with DC-CIK (128 and 85 days), CT (141 and 92 days) or supportive care only (52 and 43 days) (P<0.001). After adjusting for competing risk factors, DC-CIK combined with S-1 and receipt of 2 or more cycles of DC-CIK treatment remained independent predictors of disease free and overall survival (P<0.05). Phenotypic analysis of peripheral blood mononuclear cells demonstrated that the CD3(+), CD3(+)/CD4(+) and CD8(+)/CD28(+) T cell subsets were elevated (P <0.05), while the CD3(+)/CD8(+), CD3(+)/CD16(+)/CD56(+) and CD4(+)/CD25(+) cell subsets were significantly decreased after DC-CIK cell therapy (P <0.05). There were no grade 3 or 4 toxicities. Additionally the mutational frequency in cell-free tumor DNA (cfDNA) declined in 4/14 patients who received DC-CIK, and was associated with a more favorable survival.</p> <p> Conclusion: Treatment of advanced pancreatic cancer with combined with DC-CIK infusions and S-1 was safe, resulted in favorable PFS and OS, and modulated the peripheral blood immune repertoire.